CN116802277A - 抗trpv6单克隆抗体及其应用 - Google Patents

抗trpv6单克隆抗体及其应用 Download PDF

Info

Publication number
CN116802277A
CN116802277A CN202280010293.4A CN202280010293A CN116802277A CN 116802277 A CN116802277 A CN 116802277A CN 202280010293 A CN202280010293 A CN 202280010293A CN 116802277 A CN116802277 A CN 116802277A
Authority
CN
China
Prior art keywords
seq
antibody
antigen
binding fragment
trpv6
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280010293.4A
Other languages
English (en)
Chinese (zh)
Inventor
黄保华
谭巍
王中波
王伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tong Yi Medicine Suzhou Co ltd
Original Assignee
Tong Yi Medicine Suzhou Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tong Yi Medicine Suzhou Co ltd filed Critical Tong Yi Medicine Suzhou Co ltd
Publication of CN116802277A publication Critical patent/CN116802277A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280010293.4A 2021-01-15 2022-01-14 抗trpv6单克隆抗体及其应用 Pending CN116802277A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/072249 2021-01-15
CN2021072249 2021-01-15
CN2022100293577 2022-01-11
CN202210029357 2022-01-11
PCT/CN2022/071976 WO2022152236A1 (zh) 2021-01-15 2022-01-14 抗trpv6单克隆抗体及其应用

Publications (1)

Publication Number Publication Date
CN116802277A true CN116802277A (zh) 2023-09-22

Family

ID=82447968

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280010293.4A Pending CN116802277A (zh) 2021-01-15 2022-01-14 抗trpv6单克隆抗体及其应用

Country Status (8)

Country Link
US (1) US20260116965A1 (https=)
EP (1) EP4293044A4 (https=)
JP (1) JP2024505430A (https=)
KR (1) KR20230132450A (https=)
CN (1) CN116802277A (https=)
CA (1) CA3206472A1 (https=)
TW (1) TW202246332A (https=)
WO (1) WO2022152236A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022365387A1 (en) * 2021-10-14 2024-05-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies against extracellular epitopes of human trpv6 channel and their diagnostic and therapeutic uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1229386C (zh) * 2002-09-16 2005-11-30 上海新世界基因技术开发有限公司 具有抑癌功能的新的人蛋白及其编码序列
EP2445932B1 (en) * 2009-06-26 2018-02-28 Soricimed Biopharma Inc. Soricidin derived peptides and methods for the detection of trpv-6 cancers and drug delivery
CN105399798B (zh) * 2015-11-24 2019-11-08 广东药科大学 Trpc3抗原多肽和抗trpc3的单克隆抗体
AU2022365387A1 (en) * 2021-10-14 2024-05-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies against extracellular epitopes of human trpv6 channel and their diagnostic and therapeutic uses

Also Published As

Publication number Publication date
JP2024505430A (ja) 2024-02-06
TW202246332A (zh) 2022-12-01
CA3206472A1 (en) 2022-07-21
EP4293044A4 (en) 2025-05-28
US20260116965A1 (en) 2026-04-30
KR20230132450A (ko) 2023-09-15
EP4293044A1 (en) 2023-12-20
WO2022152236A1 (zh) 2022-07-21

Similar Documents

Publication Publication Date Title
JP6043725B2 (ja) ｉｎｖｉｖｏで抗腫瘍活性を有する抗ヒトＴＲＯＰ−２抗体
US9823251B2 (en) Anti-Uroplakin II antibodies systems and methods
JP6586648B2 (ja) 抗プログルカゴン抗体
CN105007941B (zh) 抗-lamp1抗体和抗体药物偶联物及其用途
KR20130108069A (ko) Ｈｅｒ2 항원에 대한 모노클로날 항체 및 그를 위한 용도
CN111363043B (zh) 抗cd20蛋白单克隆抗体、细胞系及其制备方法和应用
JP2020511111A (ja) 炭酸脱水素酵素に結合する抗体およびその用途
CN113735971A (zh) 抗ck18蛋白单克隆抗体及其细胞株、制备方法和应用
CN109627338B (zh) 一种新型抗人pd-l1抗体及其应用
JP2008539271A (ja) ｃｓＰＣＮＡイソ型抗体およびその使用
CN116802277A (zh) 抗trpv6单克隆抗体及其应用
JP7229503B2 (ja) ＣＡＤＭ１ｖ９認識抗体
CN113845592A (zh) 抗ck5/6蛋白单克隆抗体及其细胞株、制备方法和应用
WO2014047973A1 (zh) 特异性识别B-Raf突变蛋白的单克隆抗体、制备方法及其应用
KR20130135869A (ko) 항 단쇄 제4형 콜라겐 폴리펩타이드 항체 및 이를 포함하는 종양의 진단, 예방 또는 치료용 약제
HK40105295A (en) Anti-trpv6 monoclonal antibody and application thereof
CN108467433B (zh) 抗Napsin A蛋白的单克隆抗体及其细胞株、制备方法和应用
EP4725964A1 (en) Antibody binding to nectin-4 and use thereof
HK40123863A (zh) 抗cldn18.2抗体及其诊断用途
CN120988126A (zh) 一种用于治疗重症急性胰腺炎的抗s100a8/a9单克隆抗体及其应用
KR20260028757A (ko) 항-cldn18.2 항체 및 이의 진단적 용도
JP2026052367A (ja) 抗ペントシジンモノクローナル抗体及びその抗体を利用したペントシジン測定試薬
CN119708220A (zh) 抗人yap1蛋白单克隆抗体及其杂交瘤细胞株和应用
CN121464158A (zh) 抗Claudin18.2抗体及其制备和使用方法
NZ716839A (en) Anti-human trop-2 antibody having an antitumor activity in vivo

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination